Back to Search
Start Over
US FDA clears expanded use of Alcresta Therapeutics' RELiZORB cartridge for paediatric patients ages 2 to 5 years
- Source :
- PharmaBiz. September 1, 2023
- Publication Year :
- 2023
-
Abstract
- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced that the US Food and Drug Administration (FDA) has cleared expanded use of RELiZORB [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.762979259